-
Distribution of Acute and Chronic Kidney Disease across Clinical Phenotypes for Sepsis Chest (IF 9.6) Pub Date : 2024-03-08 Luca Molinari MD, Gaspar Del Rio-Pertuz MD, Priyanka Priyanka BAMS MPH, Ali Smith BA, Joseph C. Maggiore BSE, Jason Kennedy MS, Hernando Gomez MD MPH, Christopher W. Seymour MD MSc, John A. Kellum MD, ProCESS and ProGReSS-AKI Investigators
Sepsis is the most common cause of Acute Kidney Injury (AKI) in critically ill patients. Four phenotypes (α, β, γ, δ) for sepsis, which have different outcomes and response to treatment, were described using routine clinical data in the electronic health record. Do the frequencies of AKI, acute kidney disease (AKD), chronic kidney disease (CKD), and AKI-on-CKD differ by sepsis phenotype? Secondary
-
Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021 Chest (IF 9.6) Pub Date : 2024-03-06 Scott M. Stevens MD, Scott C. Woller MD, Lisa Baumann Kreuziger MD MS, Kevin Doerschug MD, Geert-Jan Geersing MD PhD, Frederikus A. Klok MD PhD, Christopher S. King MD, Susan Murin MD, Janine R.E. Vintch MD, Philip S. Wells MD, Suman Wasan MD, Lisa K. Moores MD
The CHEST Antithrombotic Therapy for Venous Thromboembolism Disease evidencebased guidelines are now updated in a more frequent, focused manner. Guidance statements from the most recent full guideline and two subsequent updates have not been gathered into a single source. METHODS An international panel of experts with experience in prior Antithrombotic Therapy guideline development reviewed the 2012
-
Preparing for Fellowship in Internal Medicine, with a Focus on Pulmonary and/or Critical Care Medicine – Major Principles and New Realities Chest (IF 9.6) Pub Date : 2024-03-06 Matthew C. Miles MD MEd FCCP, Peter Lenz MD FCCP, Jennifer McCallister MD FCCP ATSF, Kristin M. Burkart MD MSc FCCP ATSF, Candace Huebert MD FCCP, Jason Moore MD MS FCCM, Laura Hinkle MD ATSF, Briana Short MD, Brent Bagley MD, Gabriel Bosslet MD MA FCCP ATSF
In this manuscript, the authors provide guidance for applicants to any subspecialty in the medical specialties matching program with a particular focus on those seeking a match into a Pulmonary and/or Critical Care Medicine training program. The PAIR-Match steps (preparation, application, interview, ranking, match) are used to discuss available literature that informs this process. Preparing a fellowship
-
Atrial Arrhythmias in Patients with Pulmonary Hypertension Chest (IF 9.6) Pub Date : 2024-03-05 Kyle O’Meara MD, Gregory Stone MD, Eric Buch MD, Adam Brownstein MD, Rajan Saggar MD, Richard Channick MD, Alexander E. Sherman MD, Aron Bender MD
Atrial arrhythmia (AA) are common in patients with pulmonary hypertension (PH) and contribute to morbidity and mortality. Given the growing PH population, it is important to understand the pathophysiology, clinical impact, and management of AA in PH. AA occurs in PH with a five-year incidence of 10-25%. AA confers a higher morbidity and mortality, and restoration of normal sinus rhythm improves survival
-
Comparison between REVEAL Lite 2 and COMPERA 2.0 for risk stratification in Pulmonary Arterial Hypertension Chest (IF 9.6) Pub Date : 2024-03-04 Sandeep Sahay MD MSc, Nelson Villasmil Hernandez MD, Fredrick Wang MD, Matthew Wooten, Duc T. Nguyen MD PhD, Charles Fauvel MD, Raymond Benza, Edward A. Graviss PhD MPH
Risk stratification is the cornerstone of the management of pulmonary arterial hypertension (PAH). Current ESC/ERS guidelines recommend using the COMPERA 3-strata risk model at baseline, and the COMPERA 2.0 4-strata model at follow-up. However, the guidelines did not take into consideration other available risk scores such as REVEAL Lite 2. Is REVEAL Lite 2 better at discriminating risk than the COMPERA
-
Use of Intravenous Albumin: A Guideline from the International Collaboration for Transfusion Medicine Guidelines. Chest (IF 9.6) Pub Date : 2024-03-04 Jeannie Callum MD, Nikolaos J. Skubas MD, Aarti Bathla MPharm MPH, Homa Keshavarz PhD, Edward G. Clark MD, Bram Rochwerg MD, Dean Fergusson PhD, Sesmu Arbous MD, Seth R. Bauer PharmD, Louise China MD, Mark Fung MD, Rachel Jug MD, Michael Neill, Cary Paine MD, Katerina Pavenski MD, Prakesh S. Shah MD, Susan Robinson MD, Hua Shan MD, Zbigniew M. Szczepiorkowski MD PhD, Thierry Thevenot MD, Bovey Wu,
Albumin is commonly employed across a wide range of clinical settings to improve hemodynamics, facilitate fluid removal, and manage complications of cirrhosis. The International Collaboration for Transfusion Medicine Guidelines developed guidelines for the use of albumin in patients requiring critical care, undergoing cardiovascular surgery, kidney replacement therapy, or experiencing complications
-
Interdisciplinary Diagnosis and Management of Patients with Interstitial Lung Disease and Connective Tissue Disease Chest (IF 9.6) Pub Date : 2024-03-04 Sabina A. Guler MD PD, Tobias Scheschkowski MD, Anja Renner MSc, Lea Kämpf BSc, Matthias Gasser MD, Britta Maurer
Diagnosis of interstitial lung diseases (ILD) can be challenging, and the identification of an associated connective tissue disease (CTD) is crucial to estimate prognosis and establish the optimal treatment approach. Diagnostic delay, limited expertise and fragmented care are barriers that impede the delivery of comprehensive healthcare for patients with rare, complex and multiorgan diseases such as
-
Effect of corticosteroids on long-term humoral and memory T cell responses in follow-up visit of hospitalized COVID-19 patients Chest (IF 9.6) Pub Date : 2024-03-01 Yeming Wang, Li Guo, Guohui Fan, Yang Han, Qiao Zhang, Weiyang Wang, Lili Ren, Hui Zhang, Geng Wang, Xueyang Zhang, Tingxuan Huang, Lan Chen, Lixue Huang, Xiaoying Gu, Dan Cui, Xinming Wang, Jingchuan Zhong, Ying Wang, Hui Li, Chaolin Huang, Jianwei Wang, Bin Cao
Corticosteroids have demonstrated their beneficial effects in improving outcomes in hospitalized patients with severe COVID-19 by suppressing excessive immune responses. However, the effect of corticosteroids on the humoral and T cell responses of COVID-19 survivors one year after infection remains uncertain, as it relates to the extent of immediate, antigen-specific defense provided by protective
-
Clinical correlates of a non-plexiform vasculopathy in patients diagnosed with idiopathic pulmonary arterial hypertension. Chest (IF 9.6) Pub Date : 2024-03-01 Esther J. Nossent MD, Josien Smits MD, Celine Seegers MSc, Lilian J. Meijboom MD PhD, Anco Boonstra MD PhD, J. Aman MD PhD, F.S. De Man PhD, Harm Jan Bogaard MD PhD, Teodora Radonic MD PhD, Peter Dorfmüller MD PhD, Anton Vonk Noordegraaf MD PhD
The clinical phenotype of idiopathic pulmonary arterial hypertension (IPAH) patients has changed. . Whether or not subgroups of IPAH patients have different vascular phenotypes is a subject of debate. What are the histological patterns and their clinical correlates in patients diagnosed with IPAH or hereditary PAH? In this this cross-sectional registry study lung histology of 50 IPAH patients was qualitatively
-
The clinical frailty scale for risk stratification in patients with fibrotic interstitial lung disease Chest (IF 9.6) Pub Date : 2024-02-27 Sabina A. Guler, Daniel-Costin Marinescu, Gerard Cox, Celine Durand, Jolene H. Fisher, Amanda Grant-Orser, Gillian C. Goobie, Nathan Hambly, Kerri A. Johannson, Nasreen Khalil, Martin Kolb, Stacey Lok, Sarah MacIsaac, Helene Manganas, Veronica Marcoux, Julie Morisset, Ciaran Scallan, Shane Shapera, Kelly Sun, Boyang Zheng, Christopher J. Ryerson, Alyson W. Wong
Previous studies have shown the importance of frailty in patients with fibrotic interstitial lung disease (ILD). Is the Clinical Frailty Scale (CFS) a valid tool to improve risk stratification in patients with fibrotic ILD? Patients with fibrotic ILD were included from the prospective multicenter Canadian Registry for Pulmonary Fibrosis. The CFS was assessed using available information from initial
-
Veno-venous Extracorporeal Membrane Oxygenation (VV ECMO) Candidacy Decision-Making: Lessons and Hypotheses from a Single Center Observational Analysis Chest (IF 9.6) Pub Date : 2024-02-27 Jonah Rubin, Alison S. Witkin, Jerome C. Crowley, Eriberto Michel, David M. Furfaro, Ricardo Teijeiro-Paradis, Annette Ilg, Raghu Seethala, Sophia Zhao, Eddy Fan
Utilization of veno-venous extracorporeal membrane oxygenation (V-V ECMO) is increasing, but candidacy selection processes are variable and subject to bias. What are the reasons behind V-V ECMO candidacy decisions, and are decisions made consistently across patients? Prospective observational study of all patients, admitted or outside hospital referrals, considered for V-V ECMO at a tertiary referral
-
Abnormal exertional breathlessness on cardiopulmonary cycle exercise testing in relation to self-reported and physiological responses in chronic airflow limitation Chest (IF 9.6) Pub Date : 2024-02-27 Magnus Ekström, Pei Zhi Li, Hayley Lewthwaite, Jean Bourbeau, Wan C. Tan, Dennis Jensen
Exertional breathlessness is a cardinal symptom of cardiorespiratory disease. How does breathlessness abnormality graded using normative reference equations during cardiopulmonary exercise testing (CPET) relate to self-reported and physiological responses in people with chronic airflow limitation (CAL). Analysis of people aged ≥40 years with CAL undergoing CPET in the Canadian Cohort Obstructive Lung
-
Non-invasive electromagnetic phrenic nerve stimulation in critically ill patients – a feasibility study. Chest (IF 9.6) Pub Date : 2024-02-24 Alessandro Panelli, Aline M. Grimm, Sven Krause, Michael A. Verfuß, Bernhard Ulm, Julius J. Grunow, Hermann G. Bartels, Niklas M. Carbon, Thomas Niederhauser, Steffen Weber-Carstens, Laurent Brochard, Stefan J. Schaller
Electromagnetic stimulation of the phrenic nerve induces diaphragm contractions, but no coils for clinical use have been available. We recently demonstrated the feasibility of ventilation using bilateral transcutaneous non-invasive electromagnetic phrenic nerve stimulation (NEPNS) preoperatively in lung-healthy, normal-weight patients in a dose-dependent manner. Is NEPNS feasible in critically ill
-
International variation in severe exacerbation rates in patients with severe asthma Chest (IF 9.6) Pub Date : 2024-02-21 Tae Yoon Lee, David Price, Chandra Prakash Yadav, Rupsa Roy, Laura Lim Huey Mien, Eileen Wang, Michael E. Wechsler, David J. Jackson, John Busby, Liam G. Heaney, Paul E. Pfeffer, Bassam Mahboub, Diahn-Warng Perng (Steve), Borja G. Cosio, Luis Perez-de-Llano, Riyad Al-Lehebi, Désirée Larenas-Linnemann, Mona Al-Ahmad, Chin Kook Rhee, Takashi Iwanaga, Enrico Heffler, Giorgio Walter Canonica, Richard Costello
Exacerbation frequency strongly influences treatment choices in patients with severe asthma. What is the extent of the variability of exacerbations rate across countries and its implications in disease management? We retrieved data from the International Severe Asthma Registry, an international observational cohort of patients with a clinical diagnosis of severe asthma. We identified patients aged
-
CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma Chest (IF 9.6) Pub Date : 2024-02-20 Cendrine Godet MD, Anne-Laure Brun MD, Francis Couturaud MD PhD, François Laurent MD PhD, Jean-Pierre Frat MD PhD, Sylvain Marchand-Adam MD PhD, Frédéric Gagnadoux MD PhD, Elodie Blanchard MD, Camille Taillé MD PhD, Bruno Philippe MD, Sandrine Hirschi MD, Claire Andréjak MD PhD, Arnaud Bourdin MD PhD, Cécile Chenivesse MD PhD, Stéphane Dominique MD PhD, Gilles Mangiapan MD PhD, Marlène Murris-Espin
One of the major challenges in managing allergic bronchopulmonary aspergillosis remains consistent and reproducible assessment of response to treatment. What are the most relevant changes in CT scan parameters over time for assessing response to treatment? In this ancillary study of a randomized clinical trial (NEBULAMB), patients with asthma with available CT scan and without exacerbation during a
-
Barriers and Facilitators of Surrogates Providing Consent for Critically Ill Patients in Clinical Trials: A Qualitative Study Chest (IF 9.6) Pub Date : 2024-02-20 Dustin C. Krutsinger MD, Shannon I. Maloney PhD, Katherine R. Courtright MD, Karsten Bartels MD PhD
Enrollment into critical care clinical trials is often hampered by the need to rely on surrogate decision-makers. To identify potential interventions facilitating enrollment into critical care clinical trials, a better understanding of surrogate decision-making for critical care clinical trial enrollment is needed. What are the barriers and facilitators of critical care trial enrollment? What are surrogate
-
Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms: A Retrospective Cohort Study Chest (IF 9.6) Pub Date : 2024-02-20 Anthony D. Bai MD, Siddhartha Srivastava MD, Geneviève C. Digby MD, Vincent Girard MD, Fahad Razak MD, Amol A. Verma MD
Antibiotics with extended anaerobic coverage are used commonly to treat aspiration pneumonia, which is not recommended by current guidelines. In patients admitted to hospital for community-acquired aspiration pneumonia, does a difference exist between antibiotic therapy with limited anaerobic coverage (LAC) vs antibiotic therapy with extended anaerobic coverage (EAC) in terms of in-hospital mortality
-
Disproportionate Use of the ED by Patients 3-Years After e-Cigarette–Associated or Vaping-Associated Lung Injury Chest (IF 9.6) Pub Date : 2024-02-20 Michael S. Zhang MD PhD, Taylor Nee MBMS, Michael Lynch MD, Jason Rose MD, Alison Morris MD, Divay Chandra MD
-
Clinician- and Patient-Identified Solutions to Reduce the Fragmentation of Post-ICU Care in Australia Chest (IF 9.6) Pub Date : 2024-02-19 Nina Leggett DPT BBiomed, Kate Emery BExSci DPT, Thomas C. Rollinson BPhysio(Hons), Adam M. Deane MBBS PhD, Craig French MBBS, Jo-Anne Manski-Nankervis MBBS(Hons) CHIA PhD, Glenn Eastwood PhD GDipNurs(CritCare), Briannah Miles BBiomed(Hons), Sophie Witherspoon MD, Jonathan Stewart MRes MPhil, Mark Merolli PhD CHIA, Yasmine Ali Abdelhamid MBBS PhD, Kimberley J. Haines PhD
Critical care survivors experience multiple care transitions, with no formal follow-up care pathway. What are the potential solutions to improve the communication between treating teams and integration of care following an ICU admission, from the perspective of patients, their caregivers, intensivists, and general practitioners (GPs) from diverse socioeconomic areas? This study included a qualitative
-
Automatic Mechanical Ventilation vs Manual Bag Ventilation During CPR: A Pilot Randomized Controlled Trial Chest (IF 9.6) Pub Date : 2024-02-18 Jonghwan Shin MD PhD, Hui Jai Lee MD PhD, Kwang Nam Jin MD PhD, Jung Ho Shin MD PhD, Kyoung Min You MD PhD, Stephen Gyung Won Lee MD, Jin Hee Jung MD PhD, Kyoung Jun Song MD PhD, Jieun Pak MD MD, Tae Yun Park MD, Chang Je Park, Gi Tak Bae RN
There is insufficient evidence supporting the theory that mechanical ventilation can replace the manual ventilation method during CPR. Is using automatic mechanical ventilation feasible and comparable to the manual ventilation method during CPR? This pilot randomized controlled trial compared automatic mechanical ventilation (MV) and manual bag ventilation (BV) during CPR of out-of-hospital cardiac
-
Lung Consolidations Depth and Gas Exchange in Different Types of Neonatal Respiratory Failure: The UNION Multicenter Study Chest (IF 9.6) Pub Date : 2024-02-16 Daniele De Luca MD PhD, Anna Foti MD, Almudena Alonso-Ojembarrena MD PhD, Valentina Condò MD, Letizia Capasso MD, Roberto Raschetti MD, Luca Bonadies MD PhD, Eugenio Baraldi MD, Fabio Mosca MD, Francesco Raimondi MD PhD, UNION study group
-
Partnering With Patients With Sarcoidosis to Implement a Community Advisory Board Chest (IF 9.6) Pub Date : 2024-02-16 Leila Bushweller, Sandra Hodges, Linda Meyer, Johnie Reed, Karen Saunders, Rhonda Jenkins MPH, Kristen A. Berg PhD CRC, J. Daryl Thornton MD, Manuel L. Ribeiro Neto MD, Daniel A. Culver DO, Logan J. Harper MD
Community advisory boards (CABs) are increasingly recognized as a means of incorporating patient experience into clinical practice and research. The power of CABs is derived from engaging with community members as equals throughout the research process. Despite this, little is known of community member experience and views on best practices for running a CAB in a rare pulmonary disease. What are CAB
-
Rheumatoid Arthritis Increases the Risk of COPD: A Nationwide Retrospective Cohort Study Chest (IF 9.6) Pub Date : 2024-02-15 Chiwook Chung MD, Hyungjin Kim MD PhD, Kyungdo Han PhD, Jinhyoung Jung PhD, Yeonghee Eun MD PhD, Hyun Lee MD, Junhee Park MD, Dong Wook Shin MD PhD DrPH, Sei Won Lee MD PhD
Most reports of pulmonary manifestations in rheumatoid arthritis (RA) have been related to interstitial lung diseases. RA and COPD are both chronic inflammatory systemic diseases. Does RA increase the risk of developing COPD? Is there a difference between seropositive and seronegative RA in the risk of COPD? Using the Korean National Health Insurance Database, we screened individuals diagnosed with
-
An Update on Patient-Reported Outcomes in Asthma Chest (IF 9.6) Pub Date : 2024-02-15 Tianshi David Wu MD MHS, Zuzana Diamant MD PhD, Nicola A. Hanania MD
Patient-reported outcomes (PROs) are information provided by patients on their condition, function, well-being, or experience. Instruments to quantify PROs, called patient-reported outcome measures (PROMs), allow standardized assessment of a unique dimension of health that cannot be measured physically. Herein, we discuss how to appraise PROMs critically and provide an update on their use in asthma
-
Achieving Goals of Care Decisions in Chronic Critical Illness: A Multi-institutional Qualitative Study Chest (IF 9.6) Pub Date : 2024-02-15 Sarah K. Andersen MD, Yanran Yang PhD, Erin K. Kross MD, Barbara Haas MD PhD, Anna Geagea MD, Teresa L. May MD, Joanna Hart MD, Sean M. Bagshaw MD, Elizabeth Dzeng MD PhD MPH, Baruch Fischhoff PhD, Douglas B. White MD
Physicians, patients, and families alike perceive a need to improve how goals of care (GOC) decisions occur in chronic critical illness (CCI), but little is currently known about this decision-making process. How do intensivists from various health systems facilitate decision-making about GOC for patients with CCI? What are barriers to, and facilitators of, this decision-making process? We conducted
-
Automated Real-Time Detection of Lung Sliding Using Artificial Intelligence: A Prospective Diagnostic Accuracy Study Chest (IF 9.6) Pub Date : 2024-02-15 Hans Clausdorff Fiedler MD, Ross Prager MD, Delaney Smith MMath, Derek Wu MD, Chintan Dave MD, Jared Tschirhart MSc, Ben Wu BCS, Blake Van Berlo BESc, Richard Malthaner MD, Robert Arntfield MD
Rapid evaluation for pneumothorax is a common clinical priority. Although lung ultrasound (LUS) often is used to assess for pneumothorax, its diagnostic accuracy varies based on patient and provider factors. To enhance the performance of LUS for pulmonary pathologic features, artificial intelligence (AI)-assisted imaging has been adopted; however, the diagnostic accuracy of AI-assisted LUS (AI-LUS)
-
Pulmonary Cellular Toxicity in Alpha-1 Antitrypsin Deficiency Chest (IF 9.6) Pub Date : 2024-02-14 Kristine M. Abo MD PhD, Carly Merritt BA, Maria C. Basil MD PhD, Susan M. Lin MD, Edward Cantu MD MSCE, Michael P. Morley MS, Pushpinder Bawa PhD, Marissa Gallagher MA, Derek E. Byers MD PhD, Edward E. Morrisey PhD, Andrew A. Wilson MD
-
Health-Related Quality of Life Across the Spectrum of Pulmonary Hypertension Chest (IF 9.6) Pub Date : 2024-02-12 Aparna Balasubramanian MD, Brett Larive PhD, Evelyn M. Horn MD, Hilary M. DuBrock MD, Reena Mehra MD, Miriam Jacob MD, Anna R. Hemnes MD, Jane A. Leopold MD, Milena K. Radeva MSc, Nicholas S. Hill MD, Serpil C. Erzurum MD, Erika Berman-Rosenzweig MD, Robert Frantz MD, Franz P. Rischard MD, Gerald Beck PhD, Paul M. Hassoun MD, Stephen C. Mathai MD, PVDOMICS Study Group
Health-related quality of life (HRQOL) is frequently impaired in pulmonary arterial hypertension. However, little is known about HRQOL in other forms of pulmonary hypertension (PH). Does HRQOL vary across groups of the World Symposium on Pulmonary Hypertension (WSPH) classification system? This cross-sectional study included patients with PH from the Pulmonary Vascular Disease Phenomics (PVDOMICS)
-
The Association Between Malnutrition and High Protein Treatment on Outcomes in Critically Ill Patients: A Post Hoc Analysis of the EFFORT Protein Randomized Trial Chest (IF 9.6) Pub Date : 2024-02-12 Charles Chin Han Lew PhD, Zheng-Yii Lee PhD, Andrew G. Day MSc, Xuran Jiang MSc, Danielle Bear RD PhD, Gordon L. Jensen MD PhD, Pauline Y. Ng MBBS, Lauren Tweel RD CNSC, Angela Parillo RD LD CNSC, Daren K. Heyland MD, Charlene Compher RD PhD
Preexisting malnutrition in critically ill patients is associated with adverse clinical outcomes. Malnutrition can be diagnosed with the Global Leadership Initiative on Malnutrition using parameters such as weight loss, muscle wasting, and BMI. International critical care nutrition guidelines recommend high protein treatment to improve clinical outcomes in critically ill patients diagnosed with preexisting
-
An approach to caring for patients and family of patients dying in the ICU Chest (IF 9.6) Pub Date : 2024-02-12 Ann L. Jennerich
Death is common in the intensive care unit (ICU), and often occurs after a decision to withhold or withdraw life-sustaining therapies. Care of the dying is a core skill for ICU clinicians, requiring expert communication, primarily with family of critically ill patients. There is limited high-quality evidence to support specific practices related to the care of dying patients in the ICU, thus many of
-
Computed Cardiopulmonography for the Detection of Early Smoking-Related Changes in the Lungs of Young Individuals Who Smoke Chest (IF 9.6) Pub Date : 2024-02-10 Jennifer L. Redmond MChem, Fiona Kendall MChem, Nicholas M.J. Smith DPhil, Snapper R.M. Magor-Elliott DPhil, Rob J. Hallifax DPhil, Christopher J. Fullerton PhD, Graham Richmond PhD, John H. Couper, Grant A.D. Ritchie DPhil, Peter A. Robbins DPhil, Nayia Petousi DPhil, Nick P. Talbot DPhil
-
Impact of Structured Reporting For Lung Cancer Screening Low-Dose CT Scan Incidental Findings on Physician Management Chest (IF 9.6) Pub Date : 2024-02-10 Yukiko Kunitomo MD, Polly Sather MSN, Jonathan Killam MD, Margaret Pisani MD MPH, Martin D. Slade PhD MPH, Lynn Tanoue MD
-
Disparities in Influenza, Pneumococcal, COVID-19 Vaccine Coverage in High-Risk Adults 19 to 64 Years of Age in Southeastern Minnesota, 2010-2021 Chest (IF 9.6) Pub Date : 2024-02-09 Jamie R. Felzer MD MPH, Amy Montgomery MD MPH, Allison M. LeMahieu MS, Lila J. Finney Rutten PhD MPH, Young J. Juhn MD MPH, Chung-Il Wi MD, Robert M. Jacobson MD, Cassie C. Kennedy MD
Despite effective vaccines against influenza, pneumococcus, and COVID-19, uptake has been suboptimal. Although disparities in vaccination by race and ethnicity have been observed, what is the role of other sociodemographic in US vaccine uptake? We conducted a population-based study using the Rochester Epidemiology Project (REP), a comprehensive medical records linkage system, to assess effects of sociodemographic
-
A Case for the Evidence-Based Use of Peripheral Vasopressors Chest (IF 9.6) Pub Date : 2024-02-07 Elizabeth S. Munroe
-
Implementing Antiinflammatory Reliever Strategies in Asthma Chest (IF 9.6) Pub Date : 2024-02-07 Sandra E. Zaeh, Michelle N. Eakin, Geoffrey Chupp
-
Interpersonal Racism Contribution to Sleep Health Disparities Chest (IF 9.6) Pub Date : 2024-02-07 Robert Stansbury, Martha E. Billings
-
The Conundrum of TB vs Sarcoidosis Chest (IF 9.6) Pub Date : 2024-02-07 Vikram Damaraju, Ganga Ravindra Adimulam
-
129Xe MRI and Oscillometry of Irritant-Induced Asthma After Bronchial Thermoplasty Chest (IF 9.6) Pub Date : 2024-02-07 Marrissa J. McIntosh, Joseph J. Hofmann, Harkiran K. Kooner, Rachel L. Eddy, Grace Parraga, Constance A. Mackenzie
Irritant-induced asthma (IIA) may develop after acute inhalational exposure in individuals without preexisting asthma. The effect of bronchial thermoplasty to treat intractable, worsening IIA has not yet been described. We evaluated a previously healthy 52-year-old man after inhalation of an unknown white powder. His pulmonary function and symptoms/quality of life worsened over 4 years, despite maximal
-
-
-
Cultivating Chaplaincy in Critical Care Chest (IF 9.6) Pub Date : 2024-02-07 Laura C. McNamara, Katelynn Dalton, Virginia Brady, Jessica D’Angio, Rev Kathleen Rimer, Margaret M. Hayes
-
-
-
-
Adding Up the Value of Pulmonary Rehabilitation in COPD Chest (IF 9.6) Pub Date : 2024-02-07 Annemarie L. Lee, Angela T. Burge
-
Can We Test the Function of the Small Airways in Children Outside the Laboratory? Chest (IF 9.6) Pub Date : 2024-02-07 Heidi Makrinioti, Andrew Bush
-
Guideline Recommendations and Real-World Practice Chest (IF 9.6) Pub Date : 2024-02-07 Athol U. Wells, Claudia Ravaglia
-
A 57-Year-Old Man With Acute Onset Hypoxemia Chest (IF 9.6) Pub Date : 2024-02-07 Mansour Alkhunaizi, Owais Ulhaq, Mourad Senussi
-
A PLUS Prediction Model Provides Insights Into the Probability of Mediastinal Metastasis Chest (IF 9.6) Pub Date : 2024-02-07 David E. Ost
-
Unusual Cause of Hemoptysis in a Woman With Cystic Fibrosis Chest (IF 9.6) Pub Date : 2024-02-07 John W. Gilboy, D. O’Brien, J.B. Zuckerman
A 20-year-old patient with cystic fibrosis (CF) complicated by pansinusitis, pancreatic insufficiency, and diabetes presented to the local ED after an episode of large-volume hemoptysis at home. At baseline, she had advanced lung disease (FEV, 0.97 L; 31% predicted) and upper lobe-predominant fibrocavitary changes. She was intermittently followed at a regional lung transplant center. She was previously
-
-
A 74-Year-Old Man With Waldenström Macroglobulinemia and Progressive Dyspnea Chest (IF 9.6) Pub Date : 2024-02-07 Vasilios Tzilas, Andrew G. Nicholson, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Meletios A. Dimopoulos, Demosthenes Bouros
A 74-year-old man presented to our department with progressive dyspnea on exertion over the last year. The patient did not report any other symptoms. He had previously smoked with a 60 pack-year history. He worked in an office and did not report any environmental, occupational, or domestic exposures. His history included asymptomatic Waldenström’s macroglobulinemia that was diagnosed 18 months before
-
Sleep Education: A Narrative Review on Barriers and Opportunities to Grow a Diverse Sleep Team Chest (IF 9.6) Pub Date : 2024-02-07 A, n, i, t, a, , V, a, l, a, n, j, u, , S, h, e, l, g, i, k, a, r, , M, D, , M, H, P, E
The increased recognition of sleep-wake disorders and their effects, along with the anticipated shortage of sleep medicine specialists, heralds a concomitant need to have more health care providers with dedicated training in the evaluation and management of sleep disorders across the life span. A narrative review of published literature on sleep education was conducted and identified factors related
-
Artificial Intelligence Feedback for Bronchoscopy Training Chest (IF 9.6) Pub Date : 2024-02-07 Junfeng Huang, Jinsheng Lin, Zikai Lin, Shiyue Li, Changhao Zhong
-
Acute Dyspnea With an Infiltrative Tracheal Mass Chest (IF 9.6) Pub Date : 2024-02-07 James Villeneuve, Rajajee Selvam, Marcio M. Gomes, Carolina Souza, Paul MacPherson
A 48-year-old woman presented to the ED with a nonproductive cough, shortness of breath, and stridor. She was otherwise healthy and had never used tobacco. The patient was mildly tachycardic but otherwise hemodynamically stable, afebrile, and saturating well on room air. She did not display any signs of increased work of breathing at rest. Although auscultation of her thorax indicated good air entry
-
-
Justifying the Use of Global Lung Function-Global by Considering Race-Conscious Medicine Chest (IF 9.6) Pub Date : 2024-02-07 David A. Kaminsky